Abstract

Objectives: efficacy of Topical Timolol Drops in the Management of Pyogenic Granuloma of Lip Introduction: Pyogenic granuloma, also referred to as granuloma pyogenicum, is a prevalent, non-cancerous vascular tumor that develops in various tissues, including the skin and mucous membranes. The medically precise term for this condition is lobular capillary hemangioma. Treatment options include cauterization (either chemical or thermal), laser therapy, surgical excision, curettage, sclerotherapy, and cryotherapy. Additionally, topical timolol is gaining recognition as a non-invasive treatment option for pyogenic granulomas. Materials / method: Individuals of both genders were enrolled in the study if they had pyogenic granuloma lesions that had been present for less than six weeks. A topical application of 0.5% timolol was administered thrice daily over a period of eight weeks. Evaluations were made regarding alterations in color, size, propensity to bleed, and any side effects experienced. Results: All 10 patients demonstrated a full response within 8 weeks, and there was no recurrence observed during the 1-month follow-up. Additionally, none of the patients reported any local or systemic side effects. Conclusion: Topical timolol administered as drops may be an effective, safe, and cost-efficient treatment for mucosal pyogenic granulomas. While topical timolol could be considered for early-stage pyogenic granulomas, further studies with extended durations are necessary to evaluate the rates of resolution and recurrence.